Do analysts prefer ICCC or ABVC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmuCell 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to ICCC or ABVC?

In the previous week, ImmuCell had 3 more articles in the media than ABVC BioPharma. MarketBeat recorded 4 mentions for ImmuCell and 1 mentions for ABVC BioPharma. ImmuCell's average media sentiment score of 0.00 equaled ABVC BioPharma'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmuCell 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ABVC BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer ALDX or ABVC?

Aldeyra Therapeutics currently has a consensus target price of $5.50, suggesting a potential upside of 254.84%. Given Aldeyra Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Aldeyra Therapeutics is more favorable than ABVC BioPharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aldeyra Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ALDX or ABVC more profitable?

Aldeyra Therapeutics' return on equity of -53.14% beat ABVC BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets Aldeyra Therapeutics N/A -53.14% -34.94% ABVC BioPharma N/A -62.46% -39.99%

Does the media favor ALDX or ABVC?

In the previous week, Aldeyra Therapeutics had 2 more articles in the media than ABVC BioPharma. MarketBeat recorded 3 mentions for Aldeyra Therapeutics and 1 mentions for ABVC BioPharma. ABVC BioPharma's average media sentiment score of 0.00 beat Aldeyra Therapeutics' score of -0.66 indicating that ABVC BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aldeyra Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative ABVC BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate ABVC or HRTX?

Heron Therapeutics has a consensus target price of $2.00, suggesting a potential upside of 307.50%. Given Heron Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Heron Therapeutics is more favorable than ABVC BioPharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Heron Therapeutics 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20

Does the media refer more to ABVC or HRTX?

In the previous week, Heron Therapeutics had 8 more articles in the media than ABVC BioPharma. MarketBeat recorded 9 mentions for Heron Therapeutics and 1 mentions for ABVC BioPharma. Heron Therapeutics' average media sentiment score of 0.78 beat ABVC BioPharma's score of 0.00 indicating that Heron Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ABVC BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Heron Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is CGTX or ABVC more profitable?

Cognition Therapeutics' return on equity of -49.97% beat ABVC BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets Cognition Therapeutics N/A -49.97% -39.34% ABVC BioPharma N/A -62.46% -39.99%

Does the media favor CGTX or ABVC?

In the previous week, Cognition Therapeutics had 3 more articles in the media than ABVC BioPharma. MarketBeat recorded 4 mentions for Cognition Therapeutics and 1 mentions for ABVC BioPharma. Cognition Therapeutics' average media sentiment score of 0.50 beat ABVC BioPharma's score of 0.00 indicating that Cognition Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cognition Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ABVC BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend VRCA or ABVC?

Verrica Pharmaceuticals presently has a consensus price target of $14.50, indicating a potential upside of 185.43%. Given Verrica Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Verrica Pharmaceuticals is more favorable than ABVC BioPharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Verrica Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to VRCA or ABVC?

In the previous week, Verrica Pharmaceuticals had 4 more articles in the media than ABVC BioPharma. MarketBeat recorded 5 mentions for Verrica Pharmaceuticals and 1 mentions for ABVC BioPharma. ABVC BioPharma's average media sentiment score of 0.00 beat Verrica Pharmaceuticals' score of -0.22 indicating that ABVC BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verrica Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral ABVC BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

ABVC BioPharma (ABVC) Competitors

$1.02 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$1.02 0.00 (0.00%)

As of 04:59 AM Eastern

Compare

ABVC vs. ICCC, ALDX, HRTX, CGTX, and VRCA

Should you buy ABVC BioPharma stock or one of its competitors? MarketBeat compares ABVC BioPharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ABVC BioPharma include ImmuCell (ICCC), Aldeyra Therapeutics (ALDX), Heron Therapeutics (HRTX), Cognition Therapeutics (CGTX), and Verrica Pharmaceuticals (VRCA). These companies are all part of the "pharmaceuticals" industry.

How does ABVC BioPharma compare to ImmuCell?

ImmuCell (NASDAQ:ICCC) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, media sentiment, dividends, profitability and analyst recommendations.

ABVC BioPharma has a net margin of 0.00% compared to ImmuCell's net margin of -1.82%. ImmuCell's return on equity of -1.88% beat ABVC BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmuCell	-1.82%	-1.88%	-1.22%
ABVC BioPharma	N/A	-62.46%	-39.99%

13.5% of ImmuCell shares are held by institutional investors. Comparatively, 11.4% of ABVC BioPharma shares are held by institutional investors. 5.7% of ImmuCell shares are held by company insiders. Comparatively, 19.0% of ABVC BioPharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

ImmuCell has higher revenue and earnings than ABVC BioPharma. ImmuCell is trading at a lower price-to-earnings ratio than ABVC BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmuCell	$27.64M	3.60	-$1.04M	-$0.06	N/A
ABVC BioPharma	$510K	53.10	-$7.91M	-$0.40	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmuCell	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, ImmuCell had 3 more articles in the media than ABVC BioPharma. MarketBeat recorded 4 mentions for ImmuCell and 1 mentions for ABVC BioPharma. ImmuCell's average media sentiment score of 0.00 equaled ABVC BioPharma'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmuCell	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ABVC BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ImmuCell has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market. Comparatively, ABVC BioPharma has a beta of 0.57, meaning that its stock price is 43% less volatile than the broader market.

Summary

ImmuCell beats ABVC BioPharma on 7 of the 12 factors compared between the two stocks.

How does ABVC BioPharma compare to Aldeyra Therapeutics?

Aldeyra Therapeutics (NASDAQ:ALDX) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends, media sentiment and profitability.

ABVC BioPharma has higher revenue and earnings than Aldeyra Therapeutics. Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than ABVC BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.46	N/A
ABVC BioPharma	$510K	53.10	-$7.91M	-$0.40	N/A

59.7% of Aldeyra Therapeutics shares are held by institutional investors. Comparatively, 11.4% of ABVC BioPharma shares are held by institutional investors. 11.8% of Aldeyra Therapeutics shares are held by company insiders. Comparatively, 19.0% of ABVC BioPharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Aldeyra Therapeutics had 2 more articles in the media than ABVC BioPharma. MarketBeat recorded 3 mentions for Aldeyra Therapeutics and 1 mentions for ABVC BioPharma. ABVC BioPharma's average media sentiment score of 0.00 beat Aldeyra Therapeutics' score of -0.66 indicating that ABVC BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aldeyra Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
ABVC BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aldeyra Therapeutics currently has a consensus target price of $5.50, suggesting a potential upside of 254.84%. Given Aldeyra Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Aldeyra Therapeutics is more favorable than ABVC BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aldeyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Aldeyra Therapeutics' return on equity of -53.14% beat ABVC BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aldeyra Therapeutics	N/A	-53.14%	-34.94%
ABVC BioPharma	N/A	-62.46%	-39.99%

Aldeyra Therapeutics has a beta of 1.21, suggesting that its share price is 21% more volatile than the broader market. Comparatively, ABVC BioPharma has a beta of 0.57, suggesting that its share price is 43% less volatile than the broader market.

Summary

Aldeyra Therapeutics beats ABVC BioPharma on 8 of the 14 factors compared between the two stocks.

How does ABVC BioPharma compare to Heron Therapeutics?

ABVC BioPharma (NASDAQ:ABVC) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, media sentiment, profitability, dividends, risk and institutional ownership.

Heron Therapeutics has a consensus target price of $2.00, suggesting a potential upside of 307.50%. Given Heron Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Heron Therapeutics is more favorable than ABVC BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Heron Therapeutics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Heron Therapeutics had 8 more articles in the media than ABVC BioPharma. MarketBeat recorded 9 mentions for Heron Therapeutics and 1 mentions for ABVC BioPharma. Heron Therapeutics' average media sentiment score of 0.78 beat ABVC BioPharma's score of 0.00 indicating that Heron Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ABVC BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Heron Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

ABVC BioPharma has higher earnings, but lower revenue than Heron Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than ABVC BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ABVC BioPharma	$510K	53.10	-$7.91M	-$0.40	N/A
Heron Therapeutics	$150.71M	0.62	-$20.19M	-$0.18	N/A

ABVC BioPharma has a beta of 0.57, suggesting that its share price is 43% less volatile than the broader market. Comparatively, Heron Therapeutics has a beta of 1.65, suggesting that its share price is 65% more volatile than the broader market.

ABVC BioPharma has a net margin of 0.00% compared to Heron Therapeutics' net margin of -20.53%. ABVC BioPharma's return on equity of -62.46% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ABVC BioPharma	N/A	-62.46%	-39.99%
Heron Therapeutics	-20.53%	-7,747.30%	-8.94%

11.4% of ABVC BioPharma shares are held by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are held by institutional investors. 19.0% of ABVC BioPharma shares are held by insiders. Comparatively, 6.1% of Heron Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Heron Therapeutics beats ABVC BioPharma on 10 of the 16 factors compared between the two stocks.

How does ABVC BioPharma compare to Cognition Therapeutics?

Cognition Therapeutics (NASDAQ:CGTX) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

Cognition Therapeutics' return on equity of -49.97% beat ABVC BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cognition Therapeutics	N/A	-49.97%	-39.34%
ABVC BioPharma	N/A	-62.46%	-39.99%

43.4% of Cognition Therapeutics shares are held by institutional investors. Comparatively, 11.4% of ABVC BioPharma shares are held by institutional investors. 11.1% of Cognition Therapeutics shares are held by company insiders. Comparatively, 19.0% of ABVC BioPharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Cognition Therapeutics presently has a consensus target price of $3.33, suggesting a potential upside of 208.64%. Given Cognition Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Cognition Therapeutics is more favorable than ABVC BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Cognition Therapeutics had 3 more articles in the media than ABVC BioPharma. MarketBeat recorded 4 mentions for Cognition Therapeutics and 1 mentions for ABVC BioPharma. Cognition Therapeutics' average media sentiment score of 0.50 beat ABVC BioPharma's score of 0.00 indicating that Cognition Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cognition Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ABVC BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ABVC BioPharma has higher revenue and earnings than Cognition Therapeutics. Cognition Therapeutics is trading at a lower price-to-earnings ratio than ABVC BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.17	N/A
ABVC BioPharma	$510K	53.10	-$7.91M	-$0.40	N/A

Cognition Therapeutics has a beta of 1.78, suggesting that its share price is 78% more volatile than the broader market. Comparatively, ABVC BioPharma has a beta of 0.57, suggesting that its share price is 43% less volatile than the broader market.

Summary

Cognition Therapeutics beats ABVC BioPharma on 10 of the 14 factors compared between the two stocks.

How does ABVC BioPharma compare to Verrica Pharmaceuticals?

Verrica Pharmaceuticals (NASDAQ:VRCA) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends.

Verrica Pharmaceuticals presently has a consensus price target of $14.50, indicating a potential upside of 185.43%. Given Verrica Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Verrica Pharmaceuticals is more favorable than ABVC BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Verrica Pharmaceuticals has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market. Comparatively, ABVC BioPharma has a beta of 0.57, indicating that its share price is 43% less volatile than the broader market.

ABVC BioPharma has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -102.84%. ABVC BioPharma's return on equity of -62.46% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verrica Pharmaceuticals	-102.84%	-360.69%	-67.57%
ABVC BioPharma	N/A	-62.46%	-39.99%

ABVC BioPharma has lower revenue, but higher earnings than Verrica Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than ABVC BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verrica Pharmaceuticals	$35.58M	2.45	-$17.89M	-$1.67	N/A
ABVC BioPharma	$510K	53.10	-$7.91M	-$0.40	N/A

42.5% of Verrica Pharmaceuticals shares are held by institutional investors. Comparatively, 11.4% of ABVC BioPharma shares are held by institutional investors. 52.9% of Verrica Pharmaceuticals shares are held by company insiders. Comparatively, 19.0% of ABVC BioPharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Verrica Pharmaceuticals had 4 more articles in the media than ABVC BioPharma. MarketBeat recorded 5 mentions for Verrica Pharmaceuticals and 1 mentions for ABVC BioPharma. ABVC BioPharma's average media sentiment score of 0.00 beat Verrica Pharmaceuticals' score of -0.22 indicating that ABVC BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verrica Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
ABVC BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Verrica Pharmaceuticals and ABVC BioPharma tied by winning 8 of the 16 factors compared between the two stocks.

Get ABVC BioPharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABVC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABVC vs. The Competition

Export

Metric	ABVC BioPharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$27.08M	$11.85B	$7.00B	$12.99B
Dividend Yield	N/A	2.69%	2.58%	10.20%
P/E Ratio	-2.55	790.96	270.57	25.05
Price / Sales	53.10	972.15	659.56	107.93
Price / Cash	N/A	15.12	28.89	37.44
Price / Book	1.96	10.36	11.20	6.43
Net Income	-$7.91M	$2.78B	$3.45B	$348.10M
7 Day Performance	-1.92%	2.80%	3.39%	2.66%
1 Month Performance	-32.45%	-0.60%	-0.72%	-0.85%
1 Year Performance	-62.22%	192.58%	77.42%	23.96%

ABVC BioPharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABVC ABVC BioPharma	0.2547 of 5 stars	$1.02 flat	N/A	-62.2%	$27.08M	$510K	N/A	30
ICCC ImmuCell	0.8931 of 5 stars	$10.75 -2.9%	N/A	+65.2%	$97.29M	$27.64M	N/A	70	Upcoming Earnings
ALDX Aldeyra Therapeutics	3.1114 of 5 stars	$1.60 +3.2%	$5.50 +243.8%	-70.5%	$96.51M	N/A	N/A	10	Earnings Report
HRTX Heron Therapeutics	2.0661 of 5 stars	$0.50 -1.3%	$2.50 +395.2%	-62.8%	$95.55M	$154.90M	N/A	300	News Coverage Earnings Report Analyst Upgrade
CGTX Cognition Therapeutics	2.2469 of 5 stars	$1.06 +7.5%	$3.33 +214.5%	+43.1%	$94.87M	N/A	N/A	20	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABVC) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ABVC BioPharma (ABVC) Competitors

ABVC vs. ICCC, ALDX, HRTX, CGTX, and VRCA

How does ABVC BioPharma compare to ImmuCell?

Summary

How does ABVC BioPharma compare to Aldeyra Therapeutics?

Summary

How does ABVC BioPharma compare to Heron Therapeutics?

Summary

How does ABVC BioPharma compare to Cognition Therapeutics?

Summary

How does ABVC BioPharma compare to Verrica Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABVC vs. The Competition

ABVC BioPharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ABVC BioPharma (ABVC) Competitors

ABVC vs. ICCC, ALDX, HRTX, CGTX, and VRCA

How does ABVC BioPharma compare to ImmuCell?

Is ICCC or ABVC more profitable?

Do institutionals and insiders believe in ICCC or ABVC?

Which has higher earnings and valuation, ICCC or ABVC?

Do analysts prefer ICCC or ABVC?

Does the media refer more to ICCC or ABVC?

Which has more volatility and risk, ICCC or ABVC?

Summary

How does ABVC BioPharma compare to Aldeyra Therapeutics?

Which has preferable earnings and valuation, ALDX or ABVC?

Do insiders and institutionals have more ownership in ALDX or ABVC?

Does the media favor ALDX or ABVC?

Do analysts prefer ALDX or ABVC?

Is ALDX or ABVC more profitable?

Which has more volatility and risk, ALDX or ABVC?

Summary

How does ABVC BioPharma compare to Heron Therapeutics?

Do analysts rate ABVC or HRTX?

Does the media refer more to ABVC or HRTX?

Which has preferable valuation and earnings, ABVC or HRTX?

Which has more risk & volatility, ABVC or HRTX?

Is ABVC or HRTX more profitable?

Do insiders & institutionals hold more shares of ABVC or HRTX?

Summary

How does ABVC BioPharma compare to Cognition Therapeutics?

Is CGTX or ABVC more profitable?

Do insiders and institutionals hold more shares of CGTX or ABVC?

Do analysts prefer CGTX or ABVC?

Does the media favor CGTX or ABVC?

Which has better earnings and valuation, CGTX or ABVC?

Which has more risk & volatility, CGTX or ABVC?

Summary

How does ABVC BioPharma compare to Verrica Pharmaceuticals?

Do analysts recommend VRCA or ABVC?

Which has more volatility and risk, VRCA or ABVC?

Is VRCA or ABVC more profitable?

Which has preferable valuation & earnings, VRCA or ABVC?

Do institutionals & insiders believe in VRCA or ABVC?

Does the media refer more to VRCA or ABVC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABVC vs. The Competition

ABVC BioPharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools